Symbols / CRVO Stock $4.13 -2.59% CervoMed Inc.

Healthcare • Biotechnology • United States • NCM
CRVO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. John J. Alam M.D.
Exch · Country NCM · United States
Market Cap 38.24M
Enterprise Value 25.31M
Income -30.04M
Sales 2.09M
FCF (ttm) -16.30M
Book/sh 1.15
Cash/sh 1.40
Employees 15
Insider 10d —
IPO May 23, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.71
PEG —
P/S 18.30
P/B 3.60
P/C —
EV/EBITDA —
EV/Sales 12.12
Quick Ratio 2.87
Current Ratio 3.36
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.30
EPS next Y -2.42
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-13
Earnings (prior) 2026-05-15
ROA -72.41%
ROE -132.76%
ROIC —
Gross Margin 0.00%
Oper. Margin -14.89%
Profit Margin 0.00%
Shs Outstand 9.26M
Shs Float 5.34M
Insider Own 43.16%
Instit Own 19.43%
Short Float 4.13%
Short Ratio 4.00
Short Interest 262.81K
52W High 13.13
vs 52W High -68.55%
52W Low 2.13
vs 52W Low 93.90%
Beta -4.54
Impl. Vol. —
Rel Volume 0.95
Avg Volume 5.28M
Volume 5.02M
Target (mean) $19.50
Tgt Median $20.50
Tgt Low $9.00
Tgt High $27.00
# Analysts 6
Recom Strong_buy
Prev Close $4.24
Price $4.13
Change -2.59%
About

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.50
Mean price target
2. Current target
$4.13
Latest analyst target
3. DCF / Fair value
$-31.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.13
Low
$9.00
High
$27.00
Mean
$19.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-23 reit HC Wainwright & Co. Buy → Buy $25
2026-04-22 main D. Boral Capital Buy → Buy $31
2026-04-08 main D. Boral Capital Buy → Buy $31
2026-03-19 main D. Boral Capital Buy → Buy $31
2026-03-18 main Roth Capital Buy → Buy $11
2026-03-18 main Chardan Capital Buy → Buy $21
2026-03-16 main D. Boral Capital Buy → Buy $31
2026-03-05 main Chardan Capital Buy → Buy $15
2026-03-04 main D. Boral Capital Buy → Buy $31
2026-02-18 main D. Boral Capital Buy → Buy $31
2025-12-18 init Cantor Fitzgerald — → Overweight —
2025-12-18 reit HC Wainwright & Co. Buy → Buy $25
2025-12-05 main D. Boral Capital Buy → Buy $31
2025-12-02 main D. Boral Capital Buy → Buy $31
2025-11-11 main D. Boral Capital Buy → Buy $31
2025-11-05 up HC Wainwright & Co. Neutral → Buy $25
2025-11-04 main D. Boral Capital Buy → Buy $31
2025-09-08 reit HC Wainwright & Co. Neutral → Neutral $11
2025-08-18 main D. Boral Capital Buy → Buy $31
2025-08-12 reit Roth Capital Buy → Buy $16
News
RSS: Latest CRVO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-11 BOGER JOSHUA S Director and Beneficial Owner of more than 10% of a Class of Security — 955,414 $2.44 $2,331,210
2025-11-18 ELDER WILLIAM ROBERT General Counsel — 3,500 $8.32 $29,250
2025-11-18 WINTON MATTHEW Officer — 5,000 $7.95 $41,430
2025-11-17 GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security — 21,600 $8.46 $182,736
2025-11-17 ALAM JOHN J Chief Executive Officer — 21,600 $8.46 $182,736
2025-11-14 GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security — 7,847 $7.51 $59,101
2025-11-14 WINTON MATTHEW Officer — 10,000 $7.57 $75,700
2025-11-14 ALAM JOHN J Chief Executive Officer — 7,847 $7.51 $59,101
2025-11-12 GREGOIRE SYLVIE L Director and Beneficial Owner of more than 10% of a Class of Security — 5,553 $7.35 $40,815
2025-11-12 ELDER WILLIAM ROBERT General Counsel — 3,500 $7.44 $26,040
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
28.29
+55.23%
18.23
+133.30%
7.81
+124.80%
3.48
Research And Development
21.82
+16.06%
18.80
+122.77%
8.44
+531.40%
1.34
Selling General And Administration
10.48
+14.37%
9.17
+40.61%
6.52
+204.77%
2.14
General And Administrative Expense
10.48
+14.37%
9.17
+40.61%
6.52
+204.77%
2.14
Other Gand A
10.48
+14.37%
9.17
+40.61%
6.52
+204.77%
2.14
Other Operating Expenses
-4.01
+58.86%
-9.74
-36.29%
-7.14
—
Total Expenses
28.29
+55.23%
18.23
+133.30%
7.81
+124.80%
3.48
Operating Income
-28.29
-55.23%
-18.23
-133.30%
-7.81
-124.80%
-3.48
Total Operating Income As Reported
-28.29
-55.23%
-18.23
-133.30%
-7.81
-124.80%
-3.48
EBITDA
-28.29
-55.23%
-18.23
-133.30%
-7.81
-34.65%
-5.80
Normalized EBITDA
-28.29
-55.23%
-18.23
-133.30%
-7.81
-34.65%
-5.80
Reconciled Depreciation
—
—
—
0.00
EBIT
-28.29
-55.23%
-18.23
-133.30%
-7.81
-34.65%
-5.80
Total Unusual Items
—
—
—
0.00
Total Unusual Items Excluding Goodwill
—
—
—
0.00
Special Income Charges
—
—
—
0.00
Impairment Of Capital Assets
—
—
—
0.00
Net Income
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Pretax Income
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Net Non Operating Interest Income Expense
1.34
-31.00%
1.94
+782.94%
0.22
+255.99%
0.06
Interest Expense Non Operating
—
—
0.00
-100.00%
0.00
Net Interest Income
1.34
-31.00%
1.94
+782.94%
0.22
+255.99%
0.06
Interest Expense
—
—
0.00
-100.00%
0.00
Interest Income Non Operating
1.34
-31.00%
1.94
+782.94%
0.22
+252.63%
0.06
Interest Income
1.34
-31.00%
1.94
+782.94%
0.22
+252.63%
0.06
Other Income Expense
-0.01
-740.26%
-0.00
-100.02%
5.42
+326.93%
-2.39
Other Non Operating Income Expenses
-0.01
-740.26%
-0.00
-100.02%
5.42
+326.93%
-2.39
Tax Provision
—
—
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Net Income From Continuing Operation Net Minority Interest
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Net Income From Continuing And Discontinued Operation
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Net Income Continuous Operations
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Normalized Income
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Net Income Common Stockholders
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
-2.98
-47.52%
-2.02
-146.34%
-0.82
+92.68%
-11.20
Basic EPS
-2.98
-47.52%
-2.02
-146.34%
-0.82
+92.68%
-11.20
Basic Average Shares
9.04
+12.00%
8.07
+203.34%
2.66
+413.65%
0.52
Diluted Average Shares
9.04
+12.00%
8.07
+203.34%
2.66
+413.65%
0.52
Diluted NI Availto Com Stockholders
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Depreciation Amortization Depletion Income Statement
—
—
—
0.00
Depreciation And Amortization In Income Statement
—
—
—
0.00
Depreciation Income Statement
—
—
—
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
22.88
-46.89%
43.08
+332.00%
9.97
+139.86%
4.16
Current Assets
22.88
-46.89%
43.08
+332.34%
9.96
+139.67%
4.16
Cash Cash Equivalents And Short Term Investments
20.86
-46.39%
38.92
+399.46%
7.79
+90.37%
4.09
Cash And Cash Equivalents
8.24
-8.49%
9.00
+15.48%
7.79
+90.37%
4.09
Cash Equivalents
—
—
7.79
+90.37%
4.09
Cash Financial
—
—
—
1.59
Other Short Term Investments
12.63
-57.79%
29.92
0.00
-100.00%
12.41
Receivables
0.43
-81.06%
2.25
+146.26%
0.92
0.00
Other Receivables
0.43
-81.06%
2.25
+146.26%
0.92
—
Prepaid Assets
1.27
-33.50%
1.91
+51.64%
1.26
+1859.39%
0.06
Current Deferred Assets
0.32
0.00
—
—
Other Current Assets
—
—
—
0.11
Total Non Current Assets
0.00
0.00
-100.00%
0.01
0.00
Net PPE
—
—
—
—
Gross PPE
—
—
—
—
Goodwill And Other Intangible Assets
—
—
—
—
Other Non Current Assets
—
—
0.01
—
Total Liabilities Net Minority Interest
4.66
+20.03%
3.88
+49.45%
2.60
-93.07%
37.44
Current Liabilities
4.66
+20.03%
3.88
+49.45%
2.60
-80.27%
13.16
Payables And Accrued Expenses
3.51
+18.61%
2.96
+99.87%
1.48
+292.34%
0.38
Payables
1.49
-3.69%
1.55
+98.22%
0.78
+704.64%
0.10
Accounts Payable
1.45
-3.79%
1.51
+128.15%
0.66
+580.84%
0.10
Current Accrued Expenses
2.02
+43.18%
1.41
+101.73%
0.70
+149.16%
0.28
Pensionand Other Post Retirement Benefit Plans Current
1.06
+32.19%
0.80
-21.72%
1.03
+181.83%
0.36
Total Tax Payable
0.04
+0.00%
0.04
-66.41%
0.12
0.00
Current Debt And Capital Lease Obligation
—
—
—
12.41
Current Debt
—
—
—
12.41
Other Current Borrowings
—
—
—
12.41
Current Capital Lease Obligation
—
—
—
—
Other Current Liabilities
0.08
-28.05%
0.12
+30.71%
0.09
-31.72%
0.13
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
24.29
Long Term Debt And Capital Lease Obligation
—
—
—
—
Long Term Capital Lease Obligation
—
—
—
—
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Taxes Liabilities
—
—
—
—
Preferred Securities Outside Stock Equity
—
—
0.00
-100.00%
24.29
Stockholders Equity
18.22
-53.52%
39.20
+431.43%
7.38
+122.16%
-33.29
Common Stock Equity
—
—
—
-33.29
Capital Stock
0.01
+6.32%
0.01
+53.37%
0.01
+995.37%
0.00
Common Stock
0.01
+6.32%
0.01
+53.37%
0.01
+995.37%
0.00
Preferred Stock
0.00
0.00
0.00
—
Share Issued
9.25
+6.32%
8.70
+53.36%
5.67
+317.33%
1.36
Ordinary Shares Number
9.25
+6.32%
8.70
+53.36%
5.67
+317.33%
1.36
Additional Paid In Capital
115.91
+5.49%
109.87
+77.75%
61.81
+225.61%
18.98
Retained Earnings
-97.70
-38.12%
-70.73
-29.92%
-54.44
-4.16%
-52.27
Gains Losses Not Affecting Retained Earnings
0.01
-89.65%
0.06
0.00
+100.00%
-0.04
Other Equity Adjustments
0.01
-89.65%
0.06
—
-0.04
Total Equity Gross Minority Interest
18.22
-53.52%
39.20
+431.43%
7.38
+122.16%
-33.29
Total Capitalization
18.22
-53.52%
39.20
+431.43%
7.38
+122.16%
-33.29
Working Capital
18.22
-53.52%
39.20
+431.99%
7.37
+181.90%
-9.00
Invested Capital
18.22
-53.52%
39.20
+431.43%
7.38
+135.34%
-20.87
Total Debt
—
—
—
12.41
Net Debt
—
—
—
8.32
Capital Lease Obligations
—
—
—
—
Net Tangible Assets
18.22
-53.52%
39.20
+431.43%
7.38
+122.16%
-33.29
Tangible Book Value
18.22
-53.52%
39.20
+431.43%
7.38
+122.16%
-33.29
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-23.45
-41.86%
-16.53
-121.89%
-7.45
-189.57%
-2.57
Cash Flow From Continuing Operating Activities
-23.45
-41.86%
-16.53
-121.89%
-7.45
-189.57%
-2.57
Net Income From Continuing Operations
-26.97
-65.53%
-16.29
-650.08%
-2.17
+62.57%
-5.80
Depreciation Amortization Depletion
—
—
—
0.00
Depreciation
—
—
—
—
Depreciation And Amortization
—
—
—
0.00
Pension And Employee Benefit Expense
—
—
0.00
-100.00%
0.13
Stock Based Compensation
1.45
+3.05%
1.41
+244.85%
0.41
+22.11%
0.33
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
—
—
—
0.13
Unrealized Gain Loss On Investment Securities
—
0.00
+100.00%
-5.42
-327.05%
2.39
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
2.92
+763.07%
-0.44
-68.60%
-0.26
-168.79%
0.38
Change In Receivables
1.83
+236.48%
-1.34
-46.26%
-0.92
0.00
Change In Prepaid Assets
0.64
+199.57%
-0.64
+46.58%
-1.20
-1510.21%
0.09
Change In Payables And Accrued Expense
0.77
-50.18%
1.54
-16.98%
1.85
+528.90%
0.29
Change In Accrued Expense
0.83
+20.84%
0.69
-46.45%
1.29
+497.66%
0.22
Change In Payable
-0.07
-107.93%
0.85
+50.22%
0.57
+614.01%
0.08
Change In Account Payable
-0.07
-107.93%
0.85
+50.22%
0.57
+614.01%
0.08
Change In Other Working Capital
-0.31
—
—
—
Investing Cash Flow
18.10
+163.14%
-28.66
0.00
+100.00%
-12.24
Cash Flow From Continuing Investing Activities
18.10
+163.14%
-28.66
0.00
+100.00%
-12.24
Net PPE Purchase And Sale
—
—
—
0.00
Sale Of PPE
—
—
—
0.00
Net Investment Purchase And Sale
18.10
+163.14%
-28.66
0.00
+100.00%
-12.24
Purchase Of Investment
-25.40
+47.19%
-48.10
0.00
+100.00%
-37.99
Sale Of Investment
43.50
+123.77%
19.44
0.00
-100.00%
25.75
Financing Cash Flow
4.59
-90.11%
46.40
+316.16%
11.15
0.00
Cash Flow From Continuing Financing Activities
4.59
-90.11%
46.40
+316.16%
11.15
0.00
Net Common Stock Issuance
4.59
-90.11%
46.40
+5628.22%
0.81
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
—
—
10.34
—
Changes In Cash
-0.76
-163.32%
1.21
-67.38%
3.70
+243.79%
-2.57
Beginning Cash Position
9.00
+15.48%
7.79
+90.37%
4.09
-38.59%
6.67
End Cash Position
8.24
-8.49%
9.00
+15.48%
7.79
+90.37%
4.09
Free Cash Flow
-23.45
-41.86%
-16.53
-121.89%
-7.45
-189.57%
-2.57
Amortization Of Securities
-0.85
+29.13%
-1.21
0.00
+100.00%
-0.21
Common Stock Issuance
4.59
-90.11%
46.40
+5628.22%
0.81
0.00
Issuance Of Capital Stock
4.59
-90.11%
46.40
+5628.22%
0.81
0.00
Net Preferred Stock Issuance
—
—
—
0.01
Preferred Stock Issuance
—
—
—
0.01
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category